11. A polypeptide according to any one of claims 1 to 6 for use in the prevention or treatment of a disease or condition in a subject.

12. The polypeptide according to claim 11, wherein said disease or condition is a disease or condition mediated in whole or in part by pathogenic IgG antibodies, preferably wherein said disease or condition is listed in Table D.

13. A method for the cleavage of IgG, the method comprising contacting a sample containing IgG with a polypeptide according to any one of claims 1 to 6 under conditions which permit IgG cysteine protease activity to occur.

14. A method according to claim 13 which is carried out *ex vivo* and/or is conducted to generate Fc and Fab fragments and/or wherein the sample is a blood sample taken from a subject suffering from a disease or condition as defined in claim 12.